title: Antihyperlipidemic properties of novel N-(benzoylphenyl)-5-substituted-1H-indole-2-carboxamides in Triton WR-1339-induced hyperlipidemic rats.
abstract: In the search for new potential antihyperlipidemic agents, the present study focuses on the synthesis of novel N-(benzoylphenyl)-5-substituted-1H-indole-2-carboxamides (compounds 8-12, 15, 16, 18) and investigating their antihyperlipidemic activity using Triton WR-1339-induced hyperlipidemic rats as an experimental model. Hyperlipidemia was developed by intraperitoneal injection of Triton WR-1339 (250 mg/kg body weight). The tested animals were divided into normal control (NCG), hyperlipidemic (HG), compound 8, 9, 15, 16, 18- and bezafibrate treated groups. At a dose of 15 mg/kg body weight, compounds 9, 16, 18 and bezafibrate (100 mg/kg) significantly (p < 0.0001) reduced elevated plasma triglycerides levels after 12 h compared to the hyperlipidemic control group. However, only the group treated with compounds 9, 16 and 18 showed an obviously significant (p < 0.001) reduction in plasma total cholesterol levels after 12 h compared to the hyperlipidemic control group. Moreover, high density lipoprotein-cholesterol levels were significantly (p < 0.0001) increased in all treated groups after 12 h compared to the hyperlipidemic control group, except for compounds 8 and 15 which revealed inactive. It is therefore reasonable to assume that compounds 9, 16 and 18 may have potential in the treatment of hyperlipidemia.
authors.affiliation: University of Jordan, Amman-11942, Jordan. hiary@ju.edu.jo
authors.forename: Yusuf
authors.initials: Y
authors.lastname: Al-Hiari
authors.forename: Ghassan
authors.initials: G
authors.lastname: Shattat
authors.forename: Tariq
authors.initials: T
authors.lastname: Al-Qirim
authors.forename: Waseem
authors.initials: W
authors.lastname: El-Huneidi
authors.forename: Ghassan Abu
authors.initials: GA
authors.lastname: Sheikha
authors.forename: Suhair
authors.initials: S
authors.lastname: Hikmat
mesh_terms: D000818:Animals; D001629:Bezafibrate / Q000494:pharmacology; D008076:Cholesterol, HDL / Q000097:blood; D006949:Hyperlipidemias / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology*; D007211:Indoles / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D008297:Male; D011092:Polyethylene Glycols; D051381:Rats; D017208:Rats, Wistar; D014280:Triglycerides / Q000097:blood
chemical_list: D008076:Cholesterol, HDL; D000960:Hypolipidemic Agents; D007211:Indoles; C570553:N-(benzoylphenyl)-5-chloro-1H-indole-2-carboxamide; C570552:N-(benzoylphenyl)-5-methoxy-1H-indole-2-carboxamide; D014280:Triglycerides; D011092:Polyethylene Glycols; C016811:tyloxapol; D001629:Bezafibrate